title: The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: a placebo-controlled randomised clinical trial.
abstract: This randomised double-blind, placebo-controlled, clinical trial investigated the effect of 3 months of treatment with calcium dobesilate on endothelium-dependent vasodilation, markers of endothelial function, blood pressure, and markers of oxidation in obese, male smokers. Vascular effects may depend on the type of vessel and we, therefore, investigated both smaller arteries, i.e. resistance arteries and small arterioles, and large conduit arteries. Vascular function was measured by acetylcholine- and sodium-nitroprusside-mediated vasodilation, and capillary recruitment, in the skin microcirculation; by forearm blood flow (FBF) responses to several agonists and to N-G-monomethyl L-arginine (L-NMMA) in the forearm vascular bed; by flow-mediated vasodilation in the brachial artery; and by determination of soluble levels of vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (sICAM-1) and E-selectin. Twenty-eight individuals received dobesilate and 24 placebo. No effect of calcium dobesilate on endothelial function, blood pressure or markers of oxidation was observed compared with placebo. The difference in acetylcholine-mediated vasodilation in the microcirculation was -52.1%-point (95% confidence interval -132.8 to 28.1); in sodium-nitroprusside-mediated vasodilation in the microcirculation, 2.6%-point (-95.1 to 100.2); in capillary recruitment, 2.5%-point (-6.8 to 11.7); in acetylcholine-induced increases in FBF (n=28), 23%-point (-173 to 126); in L-NMMA-induced reduction of basal FBF, -2.8%-point (-29.3 to 23.8); in flow-mediated vasodilation of the brachial artery, 0.3%-points (-2.7 to 3.3); in 24-h systolic blood pressure, 2.1 mmHg (-1.3 to 5.5); in soluble VCAM-1, 54 ng/ml (-8 to 115); in soluble ICAM-1, 9 ng/ml (-49 to 67); in sE-selectin, -17 ng/ml (-44 to 11); in ketocholesterol 5 nM (-17 to 26); and in oxidised LDL -1.6 U/l (-6.7 to 3.5). We have shown that endothelial function, blood pressure, and markers of oxidation were not affected by 3 months of treatment with calcium dobesilate in mildly obese, smoking men. Thus, our data provide no evidence of an effect on vascular function of calcium dobesilate in humans.
authors.affiliation: Institute for Cardiovascular Research, VU University Medical Centre, Amsterdam, Netherlands.
authors.forename: Miranda T
authors.initials: MT
authors.lastname: Schram
authors.forename: Frank
authors.initials: F
authors.lastname: Stam
authors.forename: Renate T
authors.initials: RT
authors.lastname: de Jongh
authors.forename: Greetje
authors.initials: G
authors.lastname: de Vries
authors.forename: Rob A J M
authors.initials: RA
authors.lastname: van Dijk
authors.forename: Erik H
authors.initials: EH
authors.lastname: Serné
authors.forename: Deva
authors.initials: D
authors.lastname: Lampe
authors.forename: Prabath W B
authors.initials: PW
authors.lastname: Nanayakkara
authors.forename: Maarten E
authors.initials: ME
authors.lastname: Tushuizen
authors.forename: Peter G
authors.initials: PG
authors.lastname: Scheffer
authors.forename: Casper G
authors.initials: CG
authors.lastname: Schalkwijk
authors.forename: Ad M
authors.initials: AM
authors.lastname: Kamper
authors.forename: Coen D A
authors.initials: CD
authors.lastname: Stehouwer
mesh_terms: D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D002123:Calcium Dobesilate / Q000009:adverse effects / Q000627:therapeutic use*; D002196:Capillaries / Q000187:drug effects / Q000502:physiology; D003971:Diastole / Q000187:drug effects; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005500:Follow-Up Studies; D005542:Forearm / Q000098:blood supply; D006339:Heart Rate / Q000187:drug effects; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007653:Ketocholesterols / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D010084:Oxidation-Reduction; D010349:Patient Compliance; D012016:Reference Values; D012039:Regional Blood Flow / Q000187:drug effects; D012907:Smoking / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D013599:Systole / Q000187:drug effects; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use; D019323:omega-N-Methylarginine / Q000008:administration & dosage
chemical_list: D015415:Biomarkers; D004791:Enzyme Inhibitors; D006490:Hemostatics; D007653:Ketocholesterols; D008077:Lipoproteins, LDL; D020030:Nitric Oxide Donors; D014665:Vasodilator Agents; C099252:oxidized low density lipoprotein; D009599:Nitroprusside; D019323:omega-N-Methylarginine; D002123:Calcium Dobesilate; D000410:Alanine Transaminase